NGF and Alzheimer disease: After preclinical characterization and clinical trials have been performed by treating AD, Parkinson’s, and diabetic patients (Figure 2, Tables 1 and2), severe limitations in the clinical use of NGF emerged, coming from its physiological action on the sensory and autonomic systems and from the high pharmacological doses needed to obtain disease improvements.